for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Neptune Wellness Solutions Inc

NEPT.TO

Latest Trade

4.41CAD

Change

-0.06(-1.34%)

Volume

225,466

Today's Range

4.39

 - 

4.62

52 Week Range

3.31

 - 

8.60

As of on the Toronto Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
4.47
Open
4.39
Volume
225,466
3M AVG Volume
7.38
Today's High
4.62
Today's Low
4.39
52 Week High
8.60
52 Week Low
3.31
Shares Out (MIL)
92.45
Market Cap (MIL)
407.72
Forward P/E
441.00
Dividend (Yield %)
--

Next Event

Q2 2020 Neptune Wellness Solutions Inc Earnings Release

Latest Developments

More

Neptune Announces New Strategic Partnership With American Media

Neptune Wellness Solutions Posts Qtrly Total Revenues of $4.4 Million

Neptune Appoints Michael Cammarata As Chief Executive Officer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Neptune Wellness Solutions Inc

Neptune Wellness Solutions Inc. is a Canada-based cannabinoids extraction company. The Company provides with cannabinoids extraction, formulation and turnkey packaging solutions. The Company is into the development of value-added and differentiated products for the Canadian and global cannabis markets. Neptune’s activities also include the development and commercialization of turnkey nutrition solutions and patented ingredients such as maxsimil, and of a variety of marine and seed oils.

Industry

Biotechnology & Drugs

Contact Info

545 Prom du Centropolis Suite 100

+1.450.6872262

http://neptunecorp.com/

Executive Leadership

John Moretz

Chairman of the Board

Michael Taylor Cammarata

Chief Executive Officer, Director

Mario Paradis

Chief Financial Officer

Michel Timperio

Senior Vice President of Sales - Global Sales

Stephen Lijoi

Vice President - Operations

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, CAD)

2018

0.0K

2019

0.0K

2020(E)

0.1K
EPS (CAD)

2018

-0.160

2019

-0.190

2020(E)

0.010
Price To Earnings (TTM)
--
Price To Sales (TTM)
17.25
Price To Book (MRQ)
5.19
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
8.45
LT Debt To Equity (MRQ)
1.36
Return on Investment (TTM)
-33.39
Return on Equity (TTM)
-27.91

Latest News

Latest News

BRIEF-Neptune, Tetra Bio-Pharma Enter Co-Development Agreement For Purified Cannabinoid Oil-Based Products Targeting Pain, Inflammation

* NEPTUNE AND TETRA BIO-PHARMA ENTER CO-DEVELOPMENT AGREEMENT FOR PURIFIED CANNABINOID OIL-BASED PRODUCTS TARGETING PAIN AND INFLAMMATION Source text for Eikon: Further company coverage:

BRIEF-Neptune And Tetra Bio-Pharma Sign Co-Development Agreement

* NEPTUNE AND TETRA BIO-PHARMA ENTER CO-DEVELOPMENT AGREEMENT FOR PURIFIED CANNABINOID OIL-BASED PRODUCTS TARGETING PAIN AND INFLAMMATION

BRIEF-Neptune Q2 revenue C$6.8 million versus C$11.6 million

* Neptune Technologies & Bioressources Inc - gain of $23.9 million realized from sale of Krill Oil business

BRIEF-Neptune reports about 45 pct fall in Q1 revenue

* Neptune Technologies & Bioressources Inc qtrly net loss of $1.2 million versus net income of $1.3 million in prior year

BRIEF-Neptune appoints John Moretz as chairman

* Neptune announces resignation of Pierre Fitzgibbon as a director and the appointment of John Moretz as chairman

BRIEF-Neptune receives Nasdaq notification regarding minimum bid requirements

* Neptune receives nasdaq notification regarding minimum bid requirements Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up